Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q1
- 저널
- JOURNAL OF VOICE31(3) · 2017
- 피인용
- Web of Science 2Scopus 3
- FWCI (Scopus)
- 0.21
- JCR IF
- JCR 2016 1.381
- ISSN
- 0892-1997
저자
- 차원재제1저자교신저자Department of Otorhinolaryngology—Head and Neck Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
- 장전엽Department of Otorhinolaryngology—Head and Neck Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
- 왕수건Department of Otorhinolaryngology—Head and Neck Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
- 강지헌Department of Otorhinolaryngology—Head and Neck Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
- 조민규Department of Otorhinolaryngology—Head and Neck Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
초록
Objectives. Botulinum toxin (BTX) has been widely used to treat adductor spasmodic dysphonia (ADSD). Most commercially available forms of BTX require reconstitution before use, which may increase the risk of contamination and requires careful titration. Recently, a liquid-type BTX type A (BTX-A) has been developed, which should simplify the procedure and enhance its efficacy. Herein, we present a prospective pilot study to investigate the efficacy and safety of liquid-type BTX-A in the treatment of ADSD. Methods. Twenty-six consecutive liquid-type BTX-A injections were performed in 12 patients with ADSD. We included as a control group 34 consecutive patients with ADSD who had previously undergone 52 vocal fold injection procedures with freeze-dried-type BTX-A. Results. All patients in both groups had improvement of symptoms related to ADSD and period of normal voice. Most patients experienced breathiness, and the onset time, the peak response time, and the duration of breathiness were similar in both groups. The duration of effect (days) was 96.96 +/- 18.91 and 77.38 +/- 18.97 in the freeze-dried-type and the liquid-type groups, and the duration of benefit (days) was 80.02 +/- 18.24 and 62.69 +/- 19.73 in the freeze-driedtype and the liquid-type groups. To compare the efficacy between the freeze-dried-type and the liquid-type BTX-A, the sessions of the unilateral vocal fold injection were included and were categorized as group A (1 similar to 2 units BTX-A) and group B (2 similar to 3 units BTX-A), according to the dose per vocal fold. There was no significant difference of effect time between freeze-dried-type and liquid-type BTX-A groups. No adverse events related to BTX or vocal fold injection were reported. Conclusions. Liquid-type BTX-A is safe and effective for the treatment of spasmodic dysphonia. With the advantages of simple preparation, storage, and reuse and animal protein-free constituents, liquid-type BTX-A may be a good option in the treatment of spasmodic dysphonia.
키워드
Botulinum toxinSpasmodic dysphoniaVocal fold injectionLiquid-typeFocal dystoniaLARYNGEAL DYSTONIASPASTIC DYSPHONIACLINICAL-TRIALEXPERIENCEMANAGEMENTINJECTIONSEFFICACYSAFETYBOTOX
식별자
- Scopus EID
- 2-s2.0-84994385971
- WoS UID
- 000403543600018



로그인
연구물 목록으로